Aptose Biosciences (NASDAQ:APTO) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a sell rating to a hold rating in a report published on Tuesday morning.

APTO has been the topic of several other reports. HC Wainwright reiterated a buy rating and issued a $23.00 price objective on shares of Aptose Biosciences in a report on Wednesday, March 27th. Canaccord Genuity Group decreased their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a report on Thursday, May 16th. Finally, Piper Sandler reiterated an overweight rating and issued a $5.00 price objective on shares of Aptose Biosciences in a report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Aptose Biosciences currently has an average rating of Moderate Buy and an average target price of $17.50.

Aptose Biosciences Trading Down 4.4 %

NASDAQ APTO opened at $1.08 on Tuesday. Aptose Biosciences has a 1 year low of $1.06 and a 1 year high of $6.96. The firm has a market capitalization of $17.59 million, a P/E ratio of -0.17 and a beta of 1.36. The firm’s fifty day moving average price is $1.33 and its two-hundred day moving average price is $1.92.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.48) by $0.04. On average, research analysts anticipate that Aptose Biosciences will post -3.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

Several institutional investors and hedge funds have recently modified their holdings of APTO. Sigma Planning Corp acquired a new position in shares of Aptose Biosciences in the third quarter valued at about $408,000. Annandale Capital LLC lifted its position in Aptose Biosciences by 40.0% during the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 21,334 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences during the fourth quarter worth about $32,000. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.